Comment

  • 22 May 2018

    PD-L1 biomarker makes a comeback in bladder cancer

    PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of PD-1/L1 inhibitors in the disease have reported clinical benefit even...

  • 8 May 2018

    Barriers impede biosimilar market entry into the US

    Back in 2010, the FDA implemented the Biologics Price Competition and Innovation Act (BPCIA) as part of the Affordable Care Act (ACA), which created an abbreviated pathway for biosimilar drug...

  • 26 April 2018

    Colorectal cancer pipeline insight

    Within the GlobalData Pharma Intelligence Center, there are profiles of many drug candidates that focus on the prevention and treatment of colorectal cancer.

  • 25 April 2018

    Oncology: the ups and downs of enrollment in China

    GlobalData found that Oncology was the largest therapy area for clinical trials in China. Infectious Disease was the second largest area, followed by Cardiovascular, Metabolic Disorders, and Central Nervous System.

Close
Close
Close

Go Top